Related Experiment Video
Updated: Jul 12, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Recalling P446. P4501A1 (CYP1A1) opting for clinical application
Alfred G Hildebrandt1, Dieter Schwarz, Solveigh Krusekopf
1Drachenfelsstr., Bonn, Germany. abhildebrandt@aol.com
Drug Metabolism Reviews
|September 6, 2007
Summary
This review examines microsomal mixed function oxidases and the clinical relevance of Cytochrome P450 1A1 (CYP1A1). It assesses CYP1A1
Area of Science:
- Biochemistry
- Pharmacogenetics
- Molecular Toxicology
Background:
- Reviews historical spectral studies of microsomal mixed function oxidases.
- Evaluates the lasting impact and scrutiny of early findings on enzyme forms.
- Highlights the clinical significance of Cytochrome P450 1A1 (CYP1A1).
Purpose of the Study:
- To re-evaluate the significance of early spectral studies on enzyme kinetics.
- To summarize research on CYP1A1's clinical relevance, including novel investigations.
- To explore the influence of genetic variations and xenobiotics on metabolic pathways.
Main Methods:
- Review of historical spectral data and published literature.
- Analysis of clinical studies focusing on CYP1A1.
- Investigation of genetic variability and its association with disease susceptibility.
Main Results:
- Assessment of the enduring scientific value of early spectral analyses.
- Demonstration of CYP1A1's role in cancer susceptibility.
- Elucidation of differential effects of polyphenols and hyperforin on benzo[a]pyrene metabolism and steroid/fatty acid metabolite patterns.
Conclusions:
- Early spectral studies' impact is critically re-examined.
- CYP1A1 genetic variability significantly influences cancer risk.
- Polyphenols and hyperforin modulate key detoxification and toxification pathways, affecting steroid and eicosapentaenoic acid metabolism.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:17Drug Metabolism: Phase I Reactions
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...